Research progress on pathology mechanism and treatment target for diabetic sarcopenia

doi:10.12092/j.issn.1009-2501.2019.12.016

Abstract

Abstract:

Diabetes is a kind of metabolic diseases characterized by hyperglycemia. Sarcopenia is one of the common diabetic complications. Development of diabetic sarcopenia is related to ubiquitin-proteasome system,insulin resistance,oxidative stress,mitochondria damage,insulin signaling pathway and advanced glycationend products.This review summarized the pathological mechanism and treatment targets for diabetic sarcopenia based on national and international literatures.

Key words: diabetes, sarcopenia, ubiquitin-proteasome system, insulin resistance, oxidative stress

CLC Number:

R685

DING Fan, LI Wenxiong, ZHANG Jiali, ZHANG Yan. Research progress on pathology mechanism and treatment target for diabetic sarcopenia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1428-1433.

References

［1］Trierweiler H,Kisielewicz G,Hoffmann Jonasson T,et al.Sarcopenia:a chronic complication of type 2 diabetes mellitus［J］.Diabetol Metab Syndr,2018,10:25.
［2］Fung FY,Koh YLE,Malhotra R,et al.Prevalence of and factors associated with sarcopenia among multi-ethnic ambulatory older Asians with type 2 diabetes mellitus in a primary care setting［J］.BMC Geriatr,2019,19(1):122.
［3］Park SW,Goodpaster BH,Strotmeyer ES,et al.Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes:the health,aging,and body composition study［J］.Diabetes Care,2007,30(6):1507-1512.
［4］Koo BK,Roh E,Yang YS,et al.Difference between old and young adults in contribution of β-cell function and sarcopenia in developing diabetes mellitus［J］.J Diabetes Investig,2016, 7(2):233-240.
［5］Reddy SS,Shruthi K,Prabhakar YK,et al.Implication of altered ubiquitin-proteasome system and ER stress in the muscle atrophy of diabetic rats［J］.Arch Biochem Biophys,2018,639:16-25.
［6］王慧,罗勇.Atrogin-1和MuRF-1在肌肉萎缩中的作用机制及影响因素［J］.实用医学杂志,2012,28(11):1921-1922.
［7］Gomes MD,Lecker SH,Jagoe RT,et al.Atrogin-1,a muscle-specifific F-box protein highly expressed during muscle atrophy［J］.Proc Natl Acad Sci USA,2001,98(25):14440-14445.
［8］Clarke BA,Drujan D,Willis MS,et al.The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasonetreated skeletal muscle［J］.Cell Metab,2007,6(5):376-385.
［9］Chen GQ,Mou CY,Yang YQ,et al.Exercise training has beneficial anti-atrophy effects by inhibiting oxidative stress-induced MuRF1 upregulation in rats with diabetes［J］.Life Sci,2011,89(1/2):44-49.
［10］Hirata Y,Nomura K,Senga Y,et al.Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis［J］.JCI Insight,2019,4(4):e124952.
［11］Conte M,Armani A,Conte G, et al.Muscle-specific Perilipin2 down-regulation affects lipid metabolism and induces myofiber hypertrophy［J］.J Cachexia Sarcopenia Muscle,2019,10(1):95-110.
［12］Meex RCR,Blaak EE,van Loon LJC.Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes［J］.Obes Rev,20(9):1205-1217.
［13］Oost LJ,Kustermann M,Armani A,et al.Fibroblast growth factor 21 controls mitophagy and muscle mass［J］.J Cachexia Sarcopenia Muscle,2019,10(3):630-642.
［14］Yamamoto Y,Sawa R,Wake I,et al.Glucose-mediated inactivation of AMP-activated protein kinase reduces the levels of L-type amino acid transporter 1 mRNA in C2C12 cells［J］.Nutr Res,2017,47:13-20.
［15］Gan Z,Fu T,Kelly DP,et al.Skeletal muscle mitochondrial remodeling in exercise and diseases［J］.Cell Res,2018,28(10): 969-980.
［16］Lokireddy S,Wijesoma IW,Teng S,et al.The ubiquitin ligase Mul1 induces mitophagy in skeletal muscle in response to muscle-wasting stimuli［J］.Cell Metab,2012,16(5):613-624.
［17］Chung E,Campise SN,Joiner HE,et al.Effect of annatto-extracted tocotrienols and green tea polyphenols on glucose homeostasis and skeletal muscle metabolism in obese male mice［J］.J Nutr Biochem,2019,67:36-43.
［18］Wang D,Sun H,Song G,et al.Resveratrol improves muscle atrophy by modulating mitochondrial quality control in stz-induced diabetic mice［J］.Mol Nutr Food Res,2018,62(9):e1700941.
［19］Bitar MS,Al-Mulla F.A defect in Nrf2 signaling constitutes a mechanism for cellular stress hypersensitivity in a genetic rat model of type 2 diabetes［J］.Am J Physiol Endocrinol Metab,2011,301(6):E1119-1129.
［20］Bitar MS,Al-Mulla F.ROS constitute a convergence nexus in the development of IGF1 resistance and impaired wound healing in a rat model of type 2 diabetes［J］.Dis Model Mech,2012,5(3):375-388.
［21］Sriram S,Subramanian S,Juvvuna PK,et al.Myostatin induces DNA damage in skeletal muscle of streptozotocin-induced type 1 diabetic mice［J］.J Biol Chem,2014,289(9):5784-5798.
［22］Hur J,Kim M,Choi SY,et al.Isobavachalcone attenuates myotube atrophy induced by TNF-α through muscle atrophy F-box signaling and the nuclear factor erythroid 2-related factor 2 cascade［J］.Phytother Res,2019,33(2):403-411.
［23］Jiménez-Osorio AS,Monroy A,Alavez S.Curcumin and insulin resistance molecular targets and clinical evidences［J］.Biofactors,2016,42(6):561.
［24］Adachi N,Kanazawa I,Tanaka KI,et al.Insulin-like growth factor-i protects against the detrimental effects of advanced glycation end products and high glucose in myoblastic c2c12 cells［J］.Calcif Tissue Int,2019,105(1):89-96.
［25］O'Neill BT,Bhardwaj G,Penniman CM,et al.Foxo transcription factors are critical regulators of diabetes-related muscle atrophy［J］. Diabetes,2019,8(3):556-570.
［26］Zhang L,Du J,Hu Z,et al.IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting［J］.J Am Soc Nephrol,2009,20(3):604-612.
［27］Leite APO,Arago DS,Nogueira MD,et al.Modulation of renin angiotensin system components by high glucose levels in the culture of collecting duct cells［J］.J Cell Physiol,2019,234(12):22809-22818.
［28］Takao T,Horino T,Kagawa T,et al.Possible involvement of intracellular angiotensin II receptor in high-glucose-induced damage in renal proximal tubular cells［J］.J Nephrol,2011,24(2):218-224.
［29］Hamrick MW.Role of the cytokine-like hormone leptin in muscle-bone crosstalk with aging［J］.J Bone Metab,2017,24(1):1-8.
［30］Lee D,Goldberg AL.SIRT1 protein,by blocking the activities of transcription factors FoxO1 and FoxO3,inhibits muscle atrophy and promotes muscle growth［J］.J Biol Chem,2013,288(42):30515-30526.
［31］Lin L,Chen K,Abdel Khalek W,et al.Regulation of skeletal muscle oxidative capacity and muscle mass by SIRT3［J］.PLoS One,2014,9(1):e85636.
［32］Chiu HC,Chiu CY,Yang RS,et al.Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation［J］.J Cachexia Sarcopenia Muscle,2018,9(3):585-602.
［33］Wimmer RJ,Russell SJ,Schneider MF.Green tea component EGCG,insulin and IGF-1 promote nuclear efflux of atrophy-associated transcription factor Foxo1 in skeletal muscle fibers［J］.J Nutr Biochem,2015,26(12):1559-1567.
［34］Kang SH,Lee HA,Kim M,et al.Forkhead box O3 plays a role in skeletal muscle atrophy through expression of E3 ubiquitin ligases MuRF-1 and atrogin-1 in Cushing's syndrome［J］.Am J Physiol Endocrinol Metab,2017,312(6): E495-E507.
［35］Bodine SC,Stitt TN,Gonzalez M,et al.Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo［J］.Nat Cell Biol,2001,3(11):1014-1019.
［36］Matsui T,Nagoshi T,Hong EG,et al.Effects of chronic Akt activation on glucose uptake in the heart［J］.Am J Physiol Endocrinol Metab,2006,290(5):E789-797.
［37］Sawitzky M,Zeissler A,Langhammer M,et al.Phenotype selection reveals coevolution of muscle glycogen and protein and PTEN as a gate keeper for the accretion of muscle mass in adult female mice［J］.PLoS One,2012,7(6):e39711.
［38］Bentzinger CF,Romanino K,Cloetta D,et al.Skeletal muscle-specific ablation of raptor,but not of rictor,causes metabolic changes and results in muscle dystrophy［J］.Cell Metab,2008,8(5):411-424.
［39］Betz C,Stracka D,Prescianotto-Baschong C,et al.Feature Article:mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology［J］.Proc Natl Acad Sci USA,2013,110(31):12526-12534.
［40］Schieke SM,Phillips D,JP MC Jr,et al.The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity［J］.J Biol Chem,2006,281(37):27643-27652.
［41］Zheng X,Boyer L,Jin M,et al.Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration［J］.Elife,2016,5:e13378.
［42］Bitar MS,Nader J,Al-Ali W,et al.Hydrogen sulfide donor NaHS improves metabolism and reduces muscle atrophy in Type 2 Diabetes:implication for understanding sarcopenic pathophysiology［J］.Oxid Med Cell Longev,2018,6825452.
［43］Matsuyama R,Tomi M,Akanuma S,et al.Up-regulation of L-type amino acid transporter 1(LAT1) in cultured rat retinal capillary endothelial cells in response to glucose deprivation［J］.Drug Metab Pharmacokinet,2012,27(3):317-324.
［44］Diah SK,Padbury JF,Campbell WA,et al.Molecular cloning of the rat TA1/LAT-1/CD98 light chain gene promoter［J］.Biochim Biophys Acta,2001,1518(3)：267-270.
［45］Kawaguchi T,Osatomi K,Yamashita H,et al.Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase［J］.J Biol Chem,2002,277(6):3829-3835.
［46］Wang H,Wollheim CB.ChREBP rather than USF2 regulates glucose stimulation of endogenous L-pyruvate kinase expression in insulin-secreting cells［J］.J Biol Chem,2002,277(36)：32746-32752.
［47］Bijland S,Mancini SJ,Salti P.Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation［J］.Clin Sci,2013,124(8):491-507.
［48］Amin SN,Hussein UK,Yassa HD,et al.Synergistic actions of vitamin D and metformin on skeletal muscles and insulin resistance of type 2 diabetic rats［J］.J Cell Physiol,2018,233(8):5768-5779.
［49］Suter M,Riek U,Tuerk R, et al.Dissecting the role of 5′-AMP for allosteric stimulation, activation,and deactivation of amp-activated protein kinase［J］.J Biol Chem,2006,281(43):32207-32216.
［50］朱海波.调血脂创新药物IMM-H007临床前开发研究.天津:中国药学会中药与天然药物专业委员会,2015.
［51］Gledhill JR,Montgomery MG,Leslie AGW,et al.Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols［J］.Proc Natl Acad Sci USA,2007,104(34):13632-13637.
［52］Zheng J,Ramirez VD.Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phenolic phytochemicals［J］.Br J Pharmacol,2000,130(5):1115-1123.
［53］Mori H,Kuroda A,Ishizu M,et al.Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes［J］.J Diabetes Investig,2019，10(5):1332-1340.
［54］游嘉,张文健,娄晋宁.糖基化终末产物对胰岛β细胞的损伤及作用机制研究进展［J］.医学研究杂志,2015,44(7):174-176,179．
［55］Chiu CY,Yang RS,Sheu ML,et al.Advanced glycation end-products induce skeletal muscle atrophy and dysfunction in diabetic mice via a RAGE-mediated,AMPK-down-regulated,Akt pathway［J］.J Pathol,2016,238(3):470-482.

[1]	LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin. Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
[2]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[3]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[4]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[5]	LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin. The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
[6]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[7]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[8]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[9]	GUO Yixun, GUAN Xiaoyin, WANG Bo, WEI Yingda, ZHANG Yan, LIN Jianhua. Research progress on pathogenesis and potential therapeutic target of sarcopenia obesity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 341-346.
[10]	BAI Jia, YANG Hong, LI Lingling, ZHANG Yangyang, YANG Ying, LV Haihong. Study on the effect of vitamin D on diabetic neuropathy through mitochondrial/autophagy pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 214-219.
[11]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[12]	ZHU Haobin, YUE Hongmei, WU Xingdong, LIU Miaomiao, LI Yating, XU Jinhui. Research progress on the role of the Nrf2 signaling pathway in the complications associated with obstructive sleep apnea [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1283-1291.
[13]	DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo. Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
[14]	YANG Zhian, ZHAO Yan, HE Yao, LIU Weiying, YU Qin. Pyroptosis mediated renal injury caused by chronic intermittent hypoxia and the intervention effect of edaravone in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 10-18.
[15]	CAI Jing, PAN Binjing, LIU Jingfang. Research progress on the relationship between hypoglycemic drugs and sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.